BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12000818)

  • 1. Clinical practice. Aspirin for primary prevention of coronary events.
    Lauer MS
    N Engl J Med; 2002 May; 346(19):1468-74. PubMed ID: 12000818
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin for the primary prevention of cardiovascular events.
    Ferrini R; Clark B
    Am Fam Physician; 2002 Nov; 66(9):1737-8. PubMed ID: 12449273
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspirin for the primary prevention of coronary events.
    Mascitelli L; Pezzetta F
    N Engl J Med; 2002 Sep; 347(12):948; author reply 948. PubMed ID: 12240692
    [No Abstract]   [Full Text] [Related]  

  • 4. Aspirin and heart disease.
    Nurse Pract; 1996 Nov; 21(11):111-2. PubMed ID: 8933540
    [No Abstract]   [Full Text] [Related]  

  • 5. Aspirin in the prevention of cardiovascular disease in women.
    Schwartz DJ
    N Engl J Med; 2005 Jun; 352(26):2751-2; author reply 2751-2. PubMed ID: 15987927
    [No Abstract]   [Full Text] [Related]  

  • 6. Aspirin + clopidogrel therapy: how does your care compare to the evidence?
    Simmons BB; Salzman BE
    J Fam Pract; 2008 Jan; 57(1):26-32. PubMed ID: 18171566
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin use for prevention of CHD: an FP's story.
    Miser WF
    Am Fam Physician; 2005 Jan; 71(2):250-1, 253. PubMed ID: 15686298
    [No Abstract]   [Full Text] [Related]  

  • 9. [Primary prevention of coronary heart disease with aspirin].
    Kübler W
    Z Kardiol; 2004; 93 Suppl 2():II33-6. PubMed ID: 15021994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice].
    Garnier LF
    Ann Cardiol Angeiol (Paris); 1997 Oct; 46(8):507-12. PubMed ID: 9538362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy for ischemic heart disease in the elderly.
    Frishman WH; Miller KP
    Geriatrics; 1988 Dec; 43 Suppl():46-56. PubMed ID: 3056785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin for the primary prevention of coronary events.
    Mehta JL
    N Engl J Med; 2002 Sep; 347(12):948; author reply 948. PubMed ID: 12239271
    [No Abstract]   [Full Text] [Related]  

  • 13. The case against routine aspirin use for primary prevention in low-risk adults.
    Bailey AL; Smyth SS; Campbell CL
    Am Fam Physician; 2011 Jun; 83(12):1387-90. PubMed ID: 21671539
    [No Abstract]   [Full Text] [Related]  

  • 14. Effective platelet inhibition by aspirin and clopidogrel: where are we now?
    Tousoulis D; Briasoulis A; Dhamrait SS; Antoniades C; Stefanadis C
    Heart; 2009 May; 95(10):850-8. PubMed ID: 19401288
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for primary prevention. Doctors and patients should understand potential benefits and risks of aspirin treatment.
    Alkhenizan A
    BMJ; 2000 Dec; 321(7274):1472-3. PubMed ID: 11187951
    [No Abstract]   [Full Text] [Related]  

  • 17. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombolytic therapy of ischemic heart disease].
    Ishikawa K
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1621-4. PubMed ID: 9410971
    [No Abstract]   [Full Text] [Related]  

  • 19. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.